{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-409833","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2026-10-01T11:38:04+00:00","discovered_at":"2026-10-01T11:40:10.271855+00:00","generated_at":"2026-10-12T14:15:09.141599+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Monte Rosa's MRT-8102 cuts hsCRP 85%, Lp(a) 24% in GFORCE-1 Phase 1; three Phase 2 trials planned","bullets":["GFORCE-1 enrolled 108 obese subjects at elevated CVD risk; MRT-8102 at 5, 20 or 40 mg once daily achieved a median NEK7 reduction of ~80-90% across all three dose levels over 4 weeks of dosing.","Median biomarker reductions: hsCRP -85%, calprotectin -56%, IL-6 -54%, SAA -51%, S100A12 -46%, fibrinogen -28%; HMGB1 -40% and IL-1β -37% in top-quartile subjects; lipoprotein(a) -24%.","No serious adverse events reported; TEAEs in 33% of MRT-8102 subjects vs 30% on placebo, no evidence of increased infection risk, and no increases in LDL-C or triglycerides (unlike IL-6(R) blockade).","Phase 2b GFORCE-2 in stable coronary artery disease + residual inflammation expected H1 2027; GEMINI-1 in gout Q4 2026/Q1 2027 with data H2 2027; GALAXY-1 in hidradenitis suppurativa H1 2027.","Elevated baseline DAMPs and IL-1β clustered in carriers of NLRP3 risk alleles (~30% of the GFORCE-1 population), supporting a genetically enrichable higher-risk development population."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-409833","json":"https://secwatch.observer/filing/0001193125-26-409833.json","markdown":"https://secwatch.observer/filing/0001193125-26-409833.md","text":"https://secwatch.observer/filing/0001193125-26-409833.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526409833/0001193125-26-409833-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526409833/glue-20261001.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T14:15:09.141599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}